Incidence of treatment-emergent proteinuria 11 weeks [clinicaltrials_resource:1045e7f5eaebf0d7494b77d4fcc9aae9]
Approximately 17 subjects to receive palifermin. Subjects will be enrolled as follows:
PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects
Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Incidence of treatment-emergent proteinuria 11 weeks [clinicaltrials_resource:1045e7f5eaebf0d7494b77d4fcc9aae9]
Approximately 17 subjects to receive palifermin. Subjects will be enrolled as follows:
PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects
Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects.
Bio2RDF identifier
1045e7f5eaebf0d7494b77d4fcc9aae9
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:1045e7f5eaebf0d7494b77d4fcc9aae9
measure [clinicaltrials_vocabulary:measure]
Incidence of treatment-emergent proteinuria
time frame [clinicaltrials_vocabulary:time-frame]
description
Approximately 17 subjects to r ...... placebo] in up to 28 subjects.
identifier
clinicaltrials_resource:1045e7f5eaebf0d7494b77d4fcc9aae9
title
Incidence of treatment-emergent proteinuria 11 weeks
@en
type
label
Incidence of treatment-emergen ...... 5e7f5eaebf0d7494b77d4fcc9aae9]
@en